Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity

International Journal of STD and AIDS

Volumn 18, Issue 5, 2007, Pages 343-346

  Haddow, L J ^a   Wood, C W ^a   Ainsworth, Jonathan G ^a  

^a NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Cohort studies; Drug toxicity; Highly active antiretroviral therapy; Non nucleoside reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; BENZOXAZINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; BRAIN TOXICITY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CYTOTOXICITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERLACTATEMIA; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TOXICITY TESTING; AGED; CLASSIFICATION; DRUG ADMINISTRATION; DRUG TOXICITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; MIDDLE AGED; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 34447130254     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646207780749790     Document Type: Article

References (14)

1. d'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral näve patients. AIDS 2000;14:499-507
2. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001;15:185-94
3. Yuan Y, L'Italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006;7:156-62
4. BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003;4(Suppl 1):1-41
5. Brook G. BHIVA audit report and updates. 9th Annual Conference of the British HIV Association Manchester, UK, 24-26 April 2003
6. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 1998;12:1735-44
7. Brinkman K, Kakuda T. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opinion Infect Dis 2000;13:5-11
8. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998;19:481-94
9. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192-7
10. Arribas JR, Pozniak AL, Gallant JE, et al. (Study 934 Team). Superior outcome for tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naïve patients. 18th International Conference on Antiviral Research, Barcelona, Spain. 2005
11. Lichtenstein K, Amron C, Wood G, Moorman A, Holmberg S. Influence of host and disease factors on ART-associated co-morbidity. 12th Conference on Retroviruses and Opportunistic Infections Boston, USA, 2005, (paper no. 852)
12. Phillips AN, Pradier C, Lazzarin A, et al. (Eurosida study group). Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001;15:2385-95
13. Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials 2002;3:296-303
14. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63